InvestorsHub Logo
Followers 645
Posts 10598
Boards Moderated 2
Alias Born 03/07/2015

Re: None

Thursday, 11/18/2021 3:15:34 PM

Thursday, November 18, 2021 3:15:34 PM

Post# of 177
CureVac Says Preclinical Trial Shows Antibody Levels of COVID-19 Vaccine Candidate CV2CoV 'Highly Comparable' With Pfizer's mRNA Vaccine
MT NEWSWIRES 3:11 PM ET 11/18/2021

03:11 PM EST, 11/18/2021 (MT Newswires) -- CureVac(CVAC) said Thursday the extended preclinical study of the second-generation vaccine candidate, CV2CoV, showed that neutralizing antibody levels after full vaccination of animals were "highly comparable" with Pfizer (PFE) and BioNTech's (BNTX) licensed mRNA vaccine, Comirnaty.

CureVac (CVAC) is developing CV2CoV in partnership with GlaxoSmithKline (GSK). Animals were vaccinated with either 12 micrograms of CV2CoV or a 30 microgram standard dose of Comirnaty.

Data showed that targeted optimizations of a non-chemically modified mRNA can significantly improve immune responses in a preclinical model.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CVAC News